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Thyroid hormone receptors (TRs) are ligand-gated transcription factors with critical roles in de-
velopment and metabolism. Although x-ray structures of TR ligand-binding domains (LBDs) with
agonists are available, comparable structures without ligand (apo-TR) orwith antagonists are not.
It remains important to understand apo-LBD conformation and the way that it rearranges with
ligands to develop better TR pharmaceuticals. In this study, we conducted hydrogen/deuterium
exchange on TR LBDs with or without agonist (T3) or antagonist (NH3). Both ligands reduce
deuterium incorporation into LBD amide hydrogens, implying tighter overall folding of the do-
main. As predicted, mass spectroscopic analysis of individual proteolytic peptides after hydrogen/
deuterium exchange reveals that ligand increases the degree of solvent protection of regions
close to the buried ligand-binding pocket. However, there is also extensive ligand protection of
other regions, including the dimer surface at H10–H11, providing evidence for allosteric commu-
nication between the ligand-binding pocket and distant interaction surfaces. Surprisingly, C-
terminal activation helix H12, which is known to alter position with ligand, remains relatively
protected from solvent in all conditions suggesting that it is packed against the LBD irrespective
of the presence or type of ligand. T3, but not NH3, increases accessibility of the upper part of
H3–H5 to solvent, and we propose that TR H12 interacts with this region in apo-TR and that this
interaction is blockedbyT3butnotNH3.Wepresentdata fromsite-directedmutagenesis experiments
and molecular dynamics simulations that lend support to this structural model of apo-TR and its
ligand-dependent conformational changes. (Molecular Endocrinology 25: 15–31, 2011)
NURSA Molecule Pages: Nuclear Receptors: TR  ER; Ligands:Thyroid hormone  4-hydroxyta-
moxifen  NH3.
Thyroid hormone receptors (TRs) are physiologicallyimportant transcription factors that belong to the nu-
clear hormone receptor (NR) family and play roles in
regulation of cholesterol levels, metabolism and heart
function in adults (1–4). TRs mediate actions of thyroid
hormones, predominantly T3 (3,5,3 triiodo-L-thyronine)
but are transcriptionally active with and without ligands
because they bind constitutively to chromatin, often as
heterodimers with retinoid X receptors (RXRs). T3 mod-
ulates gene transcription by altering the conformation of
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the TR ligand-binding domain (LBD), which in turn alters
the complement of TR-associated coregulators (1–4).
It is important to understand how ligands influence TR
LBD conformation to develop better pharmaceuticals to
modulate receptor activity (5–8). We, and others, ob-
tained x-ray structures of TR LBDs with agonists (4, 6,
8–12). These structures, with subsequent similar struc-
tures of other NRs, reveal that the LBD adopts a canon-
ical three-dimensional fold comprised of 12 conserved
-helices (H) and 4 -strands (S) (13–18). Hormone oc-
cupies a buried ligand-binding pocket (LBP) formed by
H5–H6 on the top, byH7 andH11 on one side, and along
the opposite side by H2, S3 and S4, and H3, being en-
closed by a lid formed by the C-terminal part of H11 and
H12 (10–18). At present, x-ray structures of unliganded
(apo-) TRs or TRs with available antagonists have not
been reported. Thus, it has not been possible to perform
detailed comparisons of TR conformation in active ago-
nist-bound and unliganded and inactive states.
One hormone-dependent change in apo-TR conforma-
tion has been inferred frommutational analysis of TR and
comparison of liganded TR structures with available x-
ray structures of other apo- and antagonist-bound NR
LBDs (14–17); agonist promotes packing of C-terminal
H12 into an active position against the LBD. This event
completes a coactivator binding surface [activation func-
tion 2 (AF-2)] that includes surface-exposed hydrophobic
residues from H3 and H5 and partly occluding an over-
lapping corepressor binding surface that is also comprised
of residues from H3 and H5 but extends below the usual
position of H12 in the liganded state (15–18). Although
H12 must adopt a distinct position that fully exposes the
corepressor binding surface in the absence of ligand, the
organization of H12 in apo-TR is unknown (18).
Hormone induces other rearrangements in the LBD.
Analysis of dynamics of several NR LBDs suggests that
they are disordered without hormone (19, 20). Early
models suggested that ligand stabilizes the region near the
LBP, with the rest of the domain remaining more orga-
nized in the absence of ligand (21–23). Several specific
ligand-dependent changes have been inferred from muta-
tional analysis of TRs. First, in vitro assembly assays in-
dicate that H1, which links the LBD to the receptor DNA-
binding domain (DBD), packs tightly against the LBD
(H2–H11) with agonists (24–26). Second, analysis of
temperature (B) factors in x-ray structures of liganded
TR-LBDswith human resistance to thyroid hormone syn-
drome mutations reveals instability in the H1–H3 region
(25, 26). Because resistance to thyroid hormone mutants
retain features of apo-TR LBD conformation with ago-
nists, it is likely that the H1–H3 region is unstructured
without ligand. Last, T3-dependent rearrangements in
surface salt bridge clusters in the H7–H8 region andH11,
near the TR dimer surface, stabilize bound T3 and in-
hibit apo-TR homodimer formation (24–26). Pres-
ently, however, the true extent and function of confor-
mational changes that occur upon hormone binding are
not known.
It is also important to understand structural alterations
that occur in response to TR antagonists to comprehend
the molecular basis of their action and to provide infor-
mation for the structure-directed development of useful
antagonist compounds for treatment of thyrotoxicosis
and cardiac arrhythmias (18). We identified the first TR
antagonists, based on TR LBD x-ray structures and the
knowledge that active H12 conformation is required for
coactivator binding.We reasoned that ligands that resem-
ble native hormone with appropriately placed extensions
could compete for agonist but would dislodge H12, in-
hibiting coactivator binding and receptor activity (27).
Later, x-ray structures of estrogen receptors (ERs) reveal
that many antagonists indeed contain bulky extensions
that displace H12, which packs over the H3–H5 region of
AF-2 (7, 14, 17, 28). Our lead antagonist, NH3, is derived
from the synthetic TR agonist GC-1 and contains a 5-
nitrophenylethynyl extension predicted to dislodge H12
(27). NH3 binds TRs with nanomolar affinity, blocks TR
LBD interactions with coactivators, and antagonizes T3
responses in cell culture, tadpoles, and rats.More surpris-
ingly, NH3 also inhibits TR LBD interactions with core-
pressors, and we proposed that the ligand repositions
H12 so that it occludes the coactivator and the corepres-
sor binding surfaces (27). This idea is not proven, and the
extent to which NH3 alters other aspects of LBD confor-
mation is not clear.
Amide hydrogen/deuterium (H/D) exchange can be
used to probe protein conformation and dynamics (29–
31). In this technique, protein samples are incubated in
deuterated (D, heavy) water, and exchange of deuterium
with protein amide hydrogens (H, light isotope) is de-
tected by mass spectroscopic analysis of complete pro-
teins or individual proteolytic peptides. Because amide
hydrogens must contact solution for deuterium exchange
to occur, the increase in protein/peptide mass after incu-
bation in heavy water provides a useful index of solvent
exposure in different conditions (29–34). Several studies
confirmed that this technique yields information about
ligand-dependent structural perturbations and dynamics
of different NR (21–23, 32–34), including the full-length
peroxisome proliferator-activated receptor-RXR het-
erodimer (34). Molecular dynamics (MD) simulations
complement this method, and MD has been used to ex-
amine other aspects of LBD dynamic behavior (35–41).
Here, we use H/D exchange to probe TR LBD conforma-
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tion with or without T3 or NH3. This analysis, coupled
with TRLBDx-ray structures, prior knowledge of ligand-
dependent conformational rearrangements of the LBD,
site-directed mutagenesis experiments, and MD simula-
tions, allows us to generate specific hypotheses about
apo-LBD organization and effects of TR agonists and
antagonists on LBD structure.
Results
TR LBD characterization
Mass-spectroscopic analysis of humanTR1 LBD
preparations revealed that the protein is intact and com-
posed of dimers and monomers. The average molecular
mass of TR1 LBDmonomer (amino acids 209-461) pre-
dicted by MS-digest software is 30,049 Da (28,645 Da
from TR plus 1422 Da from His tag and linker). Mass-
spectroscopic analysis of apo-TR1 LBD preparations
reveals peaks of 60,108.1 26.8Da and 30,039.2 19.3
Da, which correspond to LBD average molecular mass of
TR dimers and monomers. The proportion of monomers
and dimers determined in apo-TR mass-spectroscopic
measurements, based on the absolute intensity of each
peak, was approximately 62 and 38% for dimers and
monomers, respectively. The monomer/dimer distribu-
tionwas consistent with previous studies of the protein by
size exclusion chromatography and native gel electro-
phoresis (10, 42). Analysis of TR1 LBD preparations
liganded to T3 and NH3 reveals that they are also com-
prised of a mix of monomers and dimers in similar con-
ditions (data not shown).
We performed pepsin digestions of apo- and liganded
TR LBD preparations and analyzed the mass of each pep-
tide by mass spectroscopy. Proteolysis generated 68 iden-
tifiable peptides, covering 92% of the amino acid se-
quence (Fig. 1). Of these, 31 peptides exhibited better
signal to noise ratio (solid underline), covering about
88% of TR1 LBD amino acid sequence, and these pep-
tides were used for H/D exchange analysis. The other
peptides were found at low intensity in the mass spec-
trum, and they cover the same region of the protein as
the selected peptides. The profile of deuterium incor-
poration for each peptide of apo-TR, TRT3, and
TRNH3 is presented in Supplemental Fig. 1 (pub-
lished on The Endocrine Society’s Journals Online web
site at http://mend.endojournals.org).
Ligand reduces LBD solvent exposure
Global mass exchange in apo-TR, TRT3 and
TRNH3 complexes was analyzed by ESI MS reveal-
ing that total deuterium incorporation increased with
incubation time in all samples. Deuterium exchange
was detected in approximately 80% of amide hydrogen
in apo-TR peptides, 48.8% in TRT3, and 47.2% in
TRNH3 peptides. Thus, the agonist (T3) and antag-
onist (NH3) both induce tighter folding of the LBD
(Fig. 2).
FIG. 1. Alignment of all peptides generated by pepsin cleavage shows almost complete coverage of the TR sequence (92%). The peptides used in
our analysis (88% of sequence coverage) are shown in continuous line.
FIG. 2. Ligand-dependent reductions in TR LBD solvent exposure.
Deuterium levels at amide bonds in the TR LBD during the total time
of the experiment for the receptor in the absence of ligand (apo TR,
light gray), in presence of agonist (TRT3, dark gray) and of
antagonist (TRNH3, medium gray). H/D exchange of the liganded-
protein is lower than apo-protein, indicative of protection against
deuterium uptake.
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Apo-TR LBD conformation
We analyzed deuterium incorporation into individual
apo-TR LBD proteolytic peptides as a function of time
and projected positions of each peptide onto x-ray struc-
tural models of T3-TR LBDs. Analysis of effects of short
(1 min) heavy water incubation implies that the apo-LBD
is well folded (Fig. 3A). Some apo-LBD peptides were
only weakly deuterated, even after long D2O incubation
times, as shown by blue color (15%D incorporation) in
the structure projection in Fig. 4A.
Analysis of positions of peptides and the extent of deu-
teration suggests that apo-LBD conformation resembles
agonist-bound LBD (Fig. 3A). Peptides with amino acids
that are predicted to form the folded core of the domain
(H1, H2, H6, H9, and H10, and -strands S2 and S3)
exhibit low deuterium incorporation (blue). By contrast,
peptides with amino acids that lie on the surface of the
domain exhibit intermediate or high levels of deuterium
incorporation (green and yellow, 15–50%, H3, H5, and
the center of H11; orange and red, 50%, the H1 C
FIG. 3. Deuterium incorporation into individual TR-LBD peptides varies with ligand. Deuterium uptake at each time point (t1 to t8 - 1, 3, 8, 15,
60, 180, 300 and 480 min, respectively) for apo-TR, TRT3 and TRNH3 is shown, respectively, in A, B and C. The rates of deuterium uptake are
color-coded: red shows an uptake over 75%; orange, from 74 to 50%; yellow, from 49 to 40%, dark green, from 39 to 25%, light green, from
24 to 15%; blue, below 14%. The secondary structure was determined by DSSP software program. -helices are given as 1 - 12, and -strands
are termed as 1 - 4. The last line represents the hydrophobicity of each residue, plotted by Texshade software. The first two residues in each
peptide are not colored because they do not participate in H/D exchange (31).
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terminus, S1,H4, andH8). Surprisingly, three parts of the
predicted protein surface appear well protected from sol-
vent; the N-terminal H0/H1 region, part of H3 in the
AF-2 surface (amino acids 280-286), and the region that
encompasses the loop between H11 and C-terminal acti-
vation H12 and H12 itself.
Deuterium incorporation into apo-TR peptides gen-
erally increased as a function of time (note progression
of color from blue through green, yellow and orange to
red in Fig. 3A). The most striking changes (15% deu-
terium incorporation after 1 min to 85% deuterium
incorporation after 5 h) involved the dimer surface (C
terminus of H10 and the N terminus of H11) and the
H5–H6 region. Thus, both regions of protein are ini-
tially protected from solvent but undergo motions that
bring them into contact with solution during the in-
cubation. Interestingly, H12 exhibited only moder-
ate deuterium incorporation during the experiment
(15%, blue, to49%, yellow), implying that it is not
highly solvent exposed. Four TR segments remained
completely protected (blue) throughout the experi-
ment: the N-terminal part of H1 (amino acids 209-
221); -strands S2 and S3; the C-terminal part of H3
(amino acids 280-286); and a fragment from the C-
terminal part of H11 and the loop between H11 and
H12 (amino acids 434-450).
FIG. 3. Continued.
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Together, our results suggest that apo-TR is well struc-
tured and that its fold resembles that of liganded LBD. In
addition, the fact that most TR peptides are, at least,
partly accessible to deuterium exchange during 5-h incu-
bations implies that apo-LBD is relatively dynamic.
T3-TR conformation
Measurement of deuterium exchange into TR-T3 com-
plex proteolytic peptides supports the conclusion that li-
gand induces a more compact configuration than apo-
LBD (Figs. 3B and 4B).Whereas deuterium incorporation
into apo-TR approached 100% after 5 h for some pep-
tides (Table 1), rates of deuterium incorporation into
T3-TR peptides reached only 67%, at best, and were usu-
ally lower (Table 1 andFig. 3B).Nearly all peptides from the
TR-T3 complex were poorly accessible after 1 min heavy
water incubations (15% incorporation, blue) (Fig. 3B and
Table 1).At this time, onlyH4, the S2/S3-sheet region, and
H8exhibited intermediate levels of deuterium incorporation
(15–49%).Most regions of TR remained inaccessible (blue)
during longer incubations or exhibited only intermediate
levels of deuterium incorporation (15 – 40%, green)
(Table 1 and Fig. 3B). Exceptions were peptides in the
loop between S1 and H3, the upper part of H3, H4, the
S3/S4 region, H8, and the center of H11, which all
exhibited more than 40% deuterium exchange.
Projection of peptides that exhibit increased solvent
protection in the presence of T3 vs. apo-TR onto struc-
FIG. 3. Continued.
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tural models of the T3-LBD complex suggests that ligand
binding altered the conformation and dynamics of the
whole domain (Fig. 3B). Several peptides that comprise
the region that envelopes the LBP (including the C termi-
nus of H1, H2, H6, and H7–H8) or comprise the hydro-
phobic core of the domain (part of H4, S2, and parts of
H9 and H10) exhibit greatly increased solvent protection
with hormone. As predicted from previous mutational
studies of TRs (see introductory section), we observed
striking increases in ligand protection of the C-terminal
part of H1, H2, S1, the loop between H2 and H3, and the
H7–H8 region.
Some peptides that comprise part of the LBP that in-
teracts with the outer ring of the ligand, including the
N-terminal part of H3, H11, the loop between H11 and
H12, and H12 itself, did not exhibit great changes in
solvent accessibility with T3. The sole difference was that
H12 exhibits a modest increase in solvent protection with
hormone [note the transition from yellow (apo) to green
(T3) for amino acids 456–461]. Equally surprising, T3
binding led to extensive protection of several regions of
the domain that are relatively distant from the LBP, in-
cluding parts of H4, H9, and the dimer surface at the
junction of H10–H11. Thus, solvent accessibility of part
of the LBD does not change greatly with hormone and
hormone-dependent structural rearrangements affect the
entire domain.
Three regions of the domain exhibited increased
rates of deuterium exchange after T3 binding, consis-
tent with increased solvent exposure (Fig. 3B). These
were S2–S3, implying that ligand binding must pro-
mote rearrangements in this region of the LBP that
bring this region into contact with solvent. More sur-
prisingly, we observed increased deuterium incorpora-
tion at the hinge/H1 region after T3 binding. This is the
first evidence that hormone alters the conformation of
this region of TR (which links the LBD to the neigh-
boring DBD). Finally, there are striking increases in
deuterium incorporation in the upper part of H3 that
comprises part of the AF-2 surface along with modest
FIG. 4. Projection of deuterium exchange rates onto structural models of TR. The TR LBD structures colored by differences in deuterium uptake,
in a gradient color, showing the deuterium incorporation after a 5-h experiment, evidencing the differences among apo-TR (A), TRT3 (B),
andTRNH3 (C). The scale from low to high D2O uptake is represented by a gradient color, from blue (protected) to red (exposed). D, Close-up
view of protected area of H3, H4, H5, and H12 for apo-TR and TRNH3, which is more exposed in TRT3. Note that the same area exhibits
greatly increased protection from solvent in inactive conformation (apo-TR and TRNH3, green to blue) when compared with active conformation
(TRT3, orange to red).
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increases in deuterium incorporation in the neighbor-
ing H4 region relative to apo-TR. Thus, hormone bind-
ing must expose the upper part of AF-2 to solvent (see
Discussion).
NH3-TR conformation
As seen with T3-TR, the NH3-TR complex appeared
more tightly packed than apo-TR.H/D exchange rates for
individual peptides reached only 60% (down from 100%
without ligand; Fig. 3C and Table 1). Most peptides ex-
hibited low levels of deuterium incorporation (blue) dur-
ing short heavy water incubations and reached interme-
diate levels (green) only after extended incubation, as seen
with T3.
Projection of positions of peptides that exhibited in-
creased protection from solvent in the presence of NH3
onto the TR-T3 structural model revealed strong similar-
ities between effects of both ligands on TR conformation.
We observed 1) concerted protection in regions of the LBP
that envelop the charged ligand carboxylate group and
inner ring, especially the region between H1 and H3, the
N terminus of H7, and the C terminus of H8; 2) few
alterations in solvent accessibility in the region of the LBP
that envelops the outer ring and 5-phenyl ring extension
TABLE 2. Mutations, location in protein structure, and effects in transactivation assays
TR mutant
Interactions in
active state
Predicted interactions in
inactive state
T3
activation
Basal
repression
F455A T3 (binding) I302 (H5)  
L456A F451 (loop H11–H12)  
E457A Coactivator T281 (H3)  
V458A L454 (H12) V284 (H3), I302(H5)  
TABLE 1. Differences in deuterium uptake after 5 h of deuteration
Structurea Sequence
Residuesb
Apo-TR
(%)c
 Error
(%)
TR-T3
(%)d
 Error
(%)
TR-NH3
(%)e
 Error
(%)
Apo-TR 
TR-T3 (%)f
Apo-TR 
TR-NH3
(%)gBeginning End
L0/H1 GHKPEPTDEEWEL 209 221 9 0.2 27 0.3 18 0.4 18 9
H1 KTVTEA 223 228 33 0.6 33 0.4 17 0.4 0 17
H1/L1 HVATNA 229 234 100 1.7 17 0.2 33 0.7 83 67
L1 TNAQGSHW 232 239 25 0.4 25 0.3 38 0.8 0 13
H2/B1 KQKRKF 240 245 100 1.7 0 0.0 33 0.7 100 67
L2 LPEDI 246 250 100 1.7 50 0.6 50 1.1 50 50
L2 PEDIGQA 247 253 50 0.9 67 0.7 33 0.7 17 17
L2 PIVNA 254 258 75 1.3 50 0.6 50 1.1 25 25
L2/H3 PEGGKVDLEA 259 268 33 0.6 22 0.2 22 0.5 11 11
H3 SHFTKI 270 275 50 0.9 50 0.6 50 1.1 0 0
H3 ITRVVDF 280 286 14 0.2 57 0.6 14 0.3 43 0
H4 PMFCEL 291 296 100 1.7 40 0.4 20 0.4 60 80
H5 PCEDQII 297 303 83 1.4 33 0.4 33 0.7 50 50
H5/H6 LKGCCMEI 305 312 63 1.1 25 0.3 13 0.3 38 50
H6 MSLRA 313 317 40 0.7 40 0.4 60 1.3 0 20
B2/B3 VRYDPESETL 319 328 22 0.4 22 0.2 11 0.2 0 11
B3/B4 TLNGEMA 329 335 57 1.0 57 0.6 29 0.6 0 29
B4/H7 VTRGQL 336 341 67 1.1 33 0.4 33 0.7 33 33
H7/H8 KNGGLGVVSDA 342 352 20 0.3 20 0.2 30 0.6 0 10
H8 DLGMSL 355 360 100 1.7 17 0.2 33 0.7 83 67
H8/L9 SSFNL 361 365 100 1.7 60 0.7 40 0.8 40 60
H9 DDTEVA 366 371 83 1.4 33 0.4 50 1.1 50 33
H9/L10 MSSDRPGL 378 386 50 0.9 38 0.4 38 0.8 13 13
L10H10 CVERIEKY 388 395 75 1.3 25 0.3 25 0.5 50 50
H10 QDSFL 396 400 100 1.7 20 0.2 60 1.3 80 40
H10H11 NYRKHHVTHF 408 417 50 0.9 0 0.0 30 0.6 50 20
H11 LMKVTDL 422 428 86 1.5 43 0.5 43 0.9 43 43
H11 RMIGA 429 433 80 1.4 40 0.4 40 0.8 40 40
H11 CHASRF 434 439 17 0.3 17 0.2 33 0.7 0 17
H11/L12 HMKVECPTELF 441 451 10 0.2 10 0.1 10 0.2 0 0
H12 EVFED 457 461 40 0.7 20 0.2 40 0.8 20 0
a Location of the peptide in protein structure.
b Number of residues in the beginning and in the end of the peptide.
c Percentage of deuterium uptake in Apo-TR.
d Percentage of deuterium uptake in TRT3.
e Percentage of deuterium uptake in TRNH3.
f Deuterium uptake difference percentage between Apo-TR and TRT3.
g Deuterium uptake difference percentage between Apo-TR and TRNH3.
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of the ligand, the N terminus of H3, H11, the loop be-
tween H11-H12 and H12; 3) marked increases in solvent
protection of several regions of protein that are distant
from the LBP, includingH9 andH11; 4) increased solvent
exposure of H0/H1 with ligand.
Several regions of the TR protein did exhibit differ-
ences in deuterium exchange rates with NH3 vs. T3 (Ta-
ble 1). Most strikingly, the C-terminal part of H3 (amino
acids 279-285) appeared well protected from solvent in
the presence of NH3 but not T3. There were also modest
increases in protection in the nearby H4 region (amino
acids 290-295) with NH3 vs. T3. These regions were also
well protected from solvent in apo-TR, suggesting that
NH3-TR conformation resembles apo-TR conformation
at this location. NH3 also gave better protection of sev-
eral regions near to the LBP relative to T3, including the
center of H1, the loop between H2 and H3, the N termi-
nus of H6 and S2–S4. Conversely, there was increased
solvent exposure of the C terminus of H6 (amino acids
313-317) and the C terminus ofH11withNH3 relative to
T3. These variations probably reflect differences in bind-
ing mode of the two ligands (see Discussion). Finally,
there were differences in regions that are relatively distant
from the LBP; NH3 increased solvent protection of H10
relative to apo-TR, but the degree of protection was less
than with T3. This implies differences in dimer surface
configuration with T3 vs. NH3.
Model of TR1 LBD in inactive conformation
suggests that H12 docks over H3
Differences between deuteration rates obtained with
different TR complexes in theH3–H5 region are shown in
Fig. 4 (A–C). Comparison of deuteration in apo-TR and
T3-TR complexes orNH3-TR andT3-TR complexes (Fig.
4D) highlight the fact that there is increased protection of
the upper part of H3 in the absence of ligand or the pres-
ence of the antagonist.
Because NR H12 docks over the H3–H5 region in the
presence of some antagonists (14, 18, 28, 42, 43), we
asked whether similar interactions could account for T3-
dependent increases in solvent accessibility of the C-ter-
minal part of H3. We created hybrid structural models
consisting of theH0 toH11 of TRLBDT3 [ProteinData
Bank (PDB) ID 3GWS] (10) and H12 from an ER-an-
tagonist structure with an inactive H12 conformation
(the ER-hydroxytamoxifen complex (PDB ID 3ERT) (43)
(Fig. 5, A and B). This model shows that H12 binds to the
same part of TR H3 that exhibits increased solvent expo-
sure with T3 (Fig. 5, C and D); this corresponds to the
upper part of the coactivator/corepressor binding surface.
Alignment of TR and ER sequences reveals only 23.7%
identity and 58% similarity between LBDs and between
the two regions that interact in our apo-TR model, the
C-terminal portion ofH3, and center ofH12 (not shown).
Nevertheless, specific residues from TR and ER H3 and
H12 that are predicted to interact are conserved (Fig. 5E).
Because the TR-ER hybrid model predicts that TR
H12 is required for optimal T3 response and masking of
the corepressor binding surface at H3–H5, we mutated
TR H12 and tested activity of mutant TRs in transacti-
vation assays with or without T3 (Fig. 6 and Table 2). As
expected, the deletion mutant F451X (which removes
H12) eliminated the T3 response at a standard T3-induc-
ible reporter (Fig. 6A). Ala substitutions at F455, L456,
E457, and F459 reduced or eliminated the T3 response,
whereas similar mutations at V458 and E460 modestly
increased activity. This is consistent with the known
structure of the T3-TR complex and previous functional
analysis (Fig. 6B); residues that are required for the T3 re-
sponse contact the hormone (F455 and F459), play a role in
packing of H12 against H3–H5 (L456), or contact coacti-
vator (E457), whereas residues that are dispensable for
the T3 response (V458 and E460) are partly or com-
pletely solvent exposed and make only weak side-chain
contacts with nearby residues (I302 on H5 and K443 in
H11, respectively).
The same mutations exhibited different effects on un-
liganded TRs. TR451X showed increased transrepres-
sion relative to unliganded wild-type TR (Fig. 6C), con-
sistent with the idea that the corepressor binding surface
is fully exposed and that TR H12 masks the corepressor
binding surface in vivo in the absence of ligand (18, 44–
46). More surprisingly, TR H12 mutations, including
TRV458A and E460Amutations that showed increased
T3 response, exhibited a similar phenotype in the absence
of ligand. Our TR-ER hybrid model (Fig. 6D) predicts
that H12 is buried in the cleft between H3 and H5, with
H12 residues in contact with the floor of the cleft (L456,
E457, and F459) or side chains of amino acids that sur-
round the cleft (V458 and E460). Thus, multiple H12
amino acids are required to suppress transrepression ca-
pacity of unliganded TR, andwe suggest that this require-
ment is consistent with the model in Fig. 5, which predicts
that multiple H12 amino acids participate in interactions
with the H3–H5 hydrophobic cleft.
MD simulations support the new apo-TR
structure model
Our structural model for apo-TR illustrates one possi-
ble H12 conformation that explains experimental results
from H/D exchange. To explore the likelihood that H12
will adopt this position without ligand, we performed a
series of MD simulations, starting from the active confor-
mation of the TR LBD, but with ligand removed.
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We did not detect H12 repositioning in the apo-TR
model under normalMD simulation conditions. Our pre-
vious MD studies revealed that the main TR ligand dis-
sociation pathway involves the mobile part of the LBD
comprising H3, the loop betweenH1 andH2, and nearby
-sheets, located opposite to H12 (39, 40), but ligand
dissociation occurred without appreciable changes in the
H12 position. We confirmed that H12 did not change
position in three independent simulations at normal tem-
perature (298 K) with or without T3 (Fig. 7). The root
mean square deviation (RMSD) between the ligand-free
LBD and the crystallographic holo structure remains con-
stant at about 1.5 Å (Fig. 7A, top panel, black line) and at
about 12.5 Å relative to the hybrid apomodel (red curve).
It is likely that displacement of H12 is kinetically sup-
pressed because of extensive packing against the body of
LBD and therefore unlikely to occur during relatively
short timeframes that are currently feasible with existing
MD simulation approaches. A similar result was obtained
in simulations of the ER LBD (37).
To increase the likelihood of observing changes in the
H12 position, we carried out three simulations at higher
temperature (498 K, Fig. 7A, lower panel) to increase sam-
pling rate of protein motions and overcome energy barriers
that prevent large-amplitude movements of H12. Although
this temperature is unrealistically high, its overall impact on
the LBD structure is not very strong in short simulation
times of the order of 10–20 nsec or less, as previously ob-
served under similar simulation conditions (47). At high
temperature, H12RMSD in the holo-TR increases from1.5
to 10.0 Å (black line, bottom panel, Fig. 7A). This means
that the structure diverges from the holo-LBD structure, as
expected in high-temperature simulations. However, the
RMSD of H12 in the apo model drops from 12.5 to about
6.5 Å. Therefore, behavior of H12 in the apo structure dif-
fers from the holo crystallographic structure.
FIG. 5. Model of TR1 LBD in inactive (apo) conformation. A, ER LBD crystal structure used as template for the modeling (gray, PDB ID 3ERT);
the H12 (dark gray) is positioning in inactive conformation, docking over H3. B, TR  T3 crystal structure (dark gray, PDB ID 3GWS), also used as
template for modeling, with H12 (light gray) in active conformation. C, The proposed model of apo-TR LBD (light gray), with the H12 (dark gray)
positioned over H3 in inactive conformation. D, Superposition of holo-TR structure and apo-TR model presenting the two different conformations
of H12: active (H12A, gray) and inactive (H12I, dark gray). E, Alignment of ER H3 and TR H3 where the residues that make contacts with H12 are
considered similar (gray); alignment of H12 of TR and of ER, where the residues that contacts H3 are similar (gray).
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Results outlined above are a consequence of the fact
that H12 adopts a new position closer to the one sug-
gested by the apo model than to the holo structure.
Comparisons of average apo-LBD structure in simula-
tions at 298 K (red) and the lowest RMSD structure
(around 6 Å) obtained from the 498 K simulations
(green) reveals H12 in a new position, docked over
H3–H5 (Fig. 7B). This is similar to our hybrid apo-TR
LBD model (gray) but distinct from the T3-TR LBD
complex (blue). Thus, MD simulations performed
without ligand predict that H12 displays tendency to
dock over the H3–H5 region.
To determine the conformational stability of the
new H12 position and to confirm that it is not depen-
dent on structural rearrangements in the LBD that are
specific for high temperature, we performed additional
simulations that started from different high-tempera-
ture apo conformations (labeled I–III, Fig. 7A) and
were cooled to 298 K to restore annealed LBD struc-
tures. The resulting annealed apo structures aligned
closely with the holo-LBD, except for H12, which re-
mained docked over H3–H5 (Fig. 7C, II/III) or trapped
in an apparent transition state between conformations
(Fig. 7, C and I). Conformational differences were de-
tected in other parts of the apo-LBD, affecting H1, H3,
H5, and the lower part of H11, which partly folds into
the open LBP as shown in Supplemental Fig. 2. Thus,
the novel apo-H12 position was preserved in annealed
apo structures, whereas organization of most LBD sec-
ondary structure elements was restored to a conforma-
tion that resembled holo-TR.
Comparisons of main polar residue interactions that
hold H12 in place in the holo (gray) and annealed apo
(color) structures were consistent with those predicted
by our hybrid TR-ER model (Fig. 7D). In the holo
structure, H12 is anchored by salt bridges between res-
idues E457, E460, and D461 with K443 and K288, in
addition hydrophobic contacts with protein and the
ligand. In structure I, H12 is caught in transition to an
inactive position in which interactions between E460/
E461 and K306 are prominent. In structures II/III, H12
is found in the suggested apo-structure conformation,
where residues D461 and K288 form a salt bridge pro-
tecting the hydrophobic region of the C terminus of H3
from hydration (see also Supplemental Fig. 2). Overall,
the computed hydration numbers of the C-terminal
portion of H3 (comprised of residues 280-285) are
markedly smaller in the apo structures II/III relative to
FIG. 6. TR H12 is needed for activity of T3-TR and unliganded TR. A, Transactivation assay for TR wild-type and TR point mutations in H12
showing responses to T3. B, Structural model of TR H12 interactions in the presence of T3 derived from T3-TR crystal structure showing positions of
key residues and interactions with protein or ligand. E457 contacts coactivator. C, Transrepression in the absence of ligand. TR H12 mutations
cause increased repression by unliganded TR. D, Structural model of TR H12 interactions in the absence of T3 derived from the ER-TR hybrid model
in Fig. 5. Note that V458 and E460 are predicted to form tight interactions with nearby residues on H3.
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TR-T3 (Supplemental Fig. 2), consistent with results of
HD exchange.
Discussion
It is important to understand apo-TR conformation and
structural alterations that occur with agonist or antago-
nist binding (see introductory section). Presently, there
are no crystal structures of apo-TR or antagonist-bound
TRs to compare with agonist-bound TR-LBD. Thus, it
has not been possible to perform detailed comparisons of
structures of TRs in different activity states.
In this study, we used H/D exchange to learn about
apo-TR LBD conformation in solution and structural alter-
ations that occur with different classes of ligands. We find
that agonist- and antagonist-liganded TRs are more com-
pact than the equivalent apo-LBDcomplex.This agreeswith
previous studies of other NRs that employed a variety of
techniques to probe domain organization, including H/D
exchange, nuclear magnetic resonance, protease sensitivity,
andmelting temperaturedetermination (19–23, 32–34, 47).
All suggest that the apo-NR LBD is mobile and that ligand
induces a tightly packed conformationally restricted state.
However, apo-TR is not completely unfolded. Analysis of
solvent protection of TR proteolytic peptides, coupled with
mapping of their positions onto TR x-ray structures, sug-
gests that apo-TR partly resembles a loosely folded version
of agonist-bound TR.
Several investigators have proposed that the NR LBP
region (roughly corresponding to the lower part of the
domain in Fig. 4) will be completely disordered without
ligand (19, 20–23). This is only partly true for TR. The
portion of the LBP that binds the T3 inner ring and amin-
opropionate group, includingH1, theH1–H3 region,H6,
and H7–H8, is indeed highly solvent exposed in apo-TR
and better protected with T3 or NH3. Interestingly, some
ligand-dependent rearrangements (involving H1, the
H1–H3 loop region, and H7–H8) were previously pre-
dicted from TRmutational analysis (see introductory sec-
tion). However, the opposite part of the LBP near the T3
outer ring (H3, H11, H11-H12 loop, and H12) is well
protected from solvent, implying that it is relatively or-
dered with or without ligands. We do not think that this
region is completely unaffected by ligand; it is well estab-
lished that H12 changes location after hormone binding.
Rather, we suggest that ligand-dependent conformational
rearrangements that affect this region involve transitions
between distinct well-ordered states (see below).
Another surprise was the extent to which ligands affect
the entire domain, not just the LBP region. We observed
increased protection of the dimer surface at the junction
of H10 and H11, indicative of allosteric communication
between the LBP and dimer surface. T3 is known to in-
hibit TR LBD homodimer formation in solution (42), and
we expected that hormone would increase overall expo-
sure of the dimer surface to solvent as dimers dissociate to
form monomers. The fact that we obtain the converse
result implies that hormone remodels the dimer surface
FIG. 7. Conformational transition from the holo-LBD structure
without ligand to apo-TR model via MD. A, RMSD of the H12 C
atoms positions in two different structural references: the TRT3
(black line) and apo-TR model conformations (red line). The upper
panel shows average RMSD of three independent simulations at
298 K. No conformational change is detected. The lower panel
depicts the RMSD of one of the three independent simulations at
498 K. There is an increase in RMSD for holo conformation and a
reduction when the reference is the proposed apo model. The
arrows indicate the three lowest RMSD structures for the apo model
(I–III) selected as starting structures to be annealed to 298 K. B,
Structural superposition of the holo-TR LBD bound to T3 (blue), the
average LBD structure obtained from simulations at 298 K (red), the
hybrid apo-TR LBD model (gray), and the lowest RMSD structure
(6 Å) for the model obtained in the simulation at 498 K (green).
Note similarities in conformations between the former two models
and later two models, respectively. C, Comparison between the
holo-TR LBD (gray) and the annealed apo-LBD average structures I
(red) and II (blue), obtained from the last 5-nsec portions of the
annealing runs. Average structures obtained from initial
conformations II and III are nearly identical. D, The main polar
interactions and hydrophobic contacts (yellow surface) between
H12 and the LBD body in the three structures.
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itself and that tight packing of this region of protein is
incompatible with homodimer formation.
Additional ligand-dependent increases in solvent pro-
tection involve H4 and H9. We have not uncovered a
function for this region of TR, but the analogous region of
the androgen receptor is needed for transcriptional activ-
ity (48). Ligand also decreased solvent protection of the
hinge and N terminus of H1, implying that the TR hinge
is packed against the LBD without hormone and exposed
with ligands (24–26). We have previously suggested (on
the basis of low-resolution x-ray structural models of TR
dimers and tetramers in solution (10, 42) that differences
in LBD conformation affect hinge organization. Our H/D
exchange data support this idea and raise the possibility
that ligand-dependent changes in hinge position could
communicate information about LBD conformation to
the nearby DBD.
The most striking ligand-dependent alteration in TR
conformation involves the C terminus of H3; T3 greatly
increases solvent accessibility of this region relative to
apo-TR and the NH3-TR complex. Although T3 could
directly increase the mobility of the AF-2 surface, we
think that the simplest explanation for this result is that
H12 packs against H3 without ligand and that T3 in-
creases solvent accessibility by altering H12 position so
that it adopts the position similar to that observed in
TR-T3 crystal structures. This hypothesis is attractive for
several reasons. First, ERH12 adopts a similar position in
ER-antagonist x-ray structures (14, 17, 28, 38), as shown
in our hybrid TR-ER model in Fig. 5. Second, it would
explain why H12 and nearby regions of the TR LBP are
protected in the apo state; H12 adopts an ordered and
discrete conformation packed against H3. Third, individ-
ual H12 residues play different roles with or without hor-
mone, suggesting that H12 adopts different positions in
the apo-TR and T3-TR complex. The fact that all C-ter-
minal amino acids are required for suppression of unli-
ganded TR activity implies that they are required for
docking of H12 into the cleft and occlusion of the core-
pressor binding site in vivo. H/D exchange results with
NH3 support this notion. Although T3 and NH3 induced
a more compact overall LBD structure, NH3 did not in-
crease solvent exposure of this segment of TR H3. Thus,
we predict thatNH3 changes LBD conformation but does
not alter H12 position relative to apo-TR; if H12 is in-
deed docked over the H3–H5 region in the presence of
NH3, this result would explain why NH3 blocks both
coactivator and corepressor binding.
Apart from differences in H3 solvent accessibility, few
aspects of TR conformation appear different with T3 and
NH3. There were subtle differences in solvent protection
pattern that can be attributed to differences in ligand-
binding mode. Several regions of TR near the LBP exhib-
ited increased solvent exposure with T3 relative to NH3,
including the C terminus of H1, part of the loop between
S1 and H3, the S2–S4 region, and H8. Conversely, the C
terminus ofH6was solvent exposedwithNH3 and less so
with T3. We cannot explain these effects without detailed
TR-NH3 atomic structures, but the fact that these pep-
tides lie near the T3 aminopropionate group suggests that
conformational differences are related to the shorter, neg-
atively charged carboxylic acid substituent at this posi-
tion in NH3. However, other differences may reflect vari-
ations in LBD allosteric communication. Unlike T3, NH3
did not induce complete protection of the dimer surface at
C terminus of H10 and the H10–H11 loop. This obser-
vation has a functional correlate; NH3 does not inhibit
TR-TR dimer formation as efficiently as T3 (27). Although
we cannot eliminate the possibility that some NH3-specific
effects on TR conformation contribute to its antagonist ac-
tions, we nevertheless note that the largest difference be-
tween T3 and NH3 involves H3 and propose that specific
changes inH12 position andAF-2 surface conformation are
most important for the ability of NH3 to block TR activity,
exactly as predicted by the extension hypothesis (18).
Our model of apo-TR H12 position has implications
for current hypotheses about TR/corepressor interac-
tions. The TR LBD corepressor binding surface is com-
posed of hydrophobic residues from H3, H5, and H6
(49). Thus, packing of H12 over H3 should block core-
pressor binding. This agrees with experimental observa-
tions; H12 truncation enhances apo-TR/corepressor in-
teractions in solution (41). Moreover, NH3 prevents TR
interactions with corepressors (50). Additionally, point
mutations that are predicted to interfere with contacts
between H12 and H3–H5 enhance unliganded TR activ-
ity, consistent with the idea that inhibit TR H12 interac-
tions with this region of the LBD surface and expose the
corepressor binding site in vivo.MD simulations also lend
support to hypothesis by revealing spontaneous, nonin-
duced, H12 conformational transitions from ligand-free
holo-TR LBD to structures very similar to the proposed
apo-TR LBD model, in which the corepressor binding
surface will be occluded.
Finally, it is interesting to compare H/D exchange re-
sults for TRs with published studies for other NRs.
Whereas we observed strong solvent protection of TR
H11 and H12 in the absence and presence of different
ligands, other groups observed that glucocorticoid recep-
tor H11 and H12 becomes more exposed with antagonist
(RU486) relative to agonist and that RXR agonists de-
creased deuterium incorporation into H11 but not H12
(21, 23). These studies suggest that there are consider-
able differences between NRs in terms of response of
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H11–H12 to ligands. It will be important to under-
stand these influences to design ligands to control TR
and NR activity.
Materials and Methods
Protein expression and purification
HumanTRLBD (residues 209-461), fused in frame to the C
terminus of a poly-histidine (his) tag in a pET dueT plasmid
(Novagen, Darmstadt, Germany), was expressed in the Esche-
richia coli strain BL21 (DE3) as described (51). After purifica-
tion, protein buffer was changed to 50 mM ammonium acetate
(pH 7.0) using a HiTrap desalting column (GE Healthcare, Pis-
cataway, NJ) because we found that this buffer provided best
results for mass spectroscopic analysis. To produce liganded
TRs, T3 (Sigma Chemical Co., St. Louis, MO) or NH3 was
added in a 3-fold molar excess and incubated for 1 h at 4 C. The
protein was concentrated up to 12-fold by ultrafiltration (Ami-
con Ultra 10MWCO;Millipore, Billerica,MA). Protein concen-
tration was determined by Bradford assay, and purity was as-
sessed by Coomassie Blue-stained SDS-PAGE.
Sample preparation and H/D exchange
H/D exchange was initiated with TR1 LBD by 3.5-fold
dilution of the protein in the same buffer in D2O (pD 7.0) at 25
C with or without ligands (70% D2O). The samples were
incubated for various times (1, 3, 8, 15, 60, 180, and 300 min),
at which point 70-l TR aliquots were added to 60 l of 20 mM
Na-phosphate buffer to quench the reaction (pH 2.5). The
samples were immediately applied onto a Quattro II triple-qua-
drupole mass spectrometer (Micromass, Altrincham, UK),
equipped with a standard electrospray ionization source, or di-
gested with pepsin (1 mol enzyme per 10 TR protein) at  0 C
for 5 min and then applied to the mass spectrometer as above.
Sequence identification of
pepsin-generated peptides
Deuterium level for each peptide was determined from the
differences in centroid masses between the deuterated and non-
deuterated fragments. The nondigested protein, after deutera-
tion, was used as a control, being compared with the total deu-
terium incorporated into the peptides, to estimate deuterium
loss during the protein digestion. This procedure was applied to
both nonliganded and liganded protein.
Data analysis
The MS-Digest software (52) was used to identify the se-
quence of selected peptide ions and to calculate the protein
molecular weight to compare these data with those acquired
from deconvolution of each spectra measurement for all sam-
ples. Total H/D exchange was calculated as the total number of
peptides bound plus one N-terminal hydrogen per peptide mi-
nus the number of proline residues. The secondary structure of
the protein was calculated by the DSSP program (53). Deutera-
tion rates and hydrophobicity were plotted using TexShade soft-
ware (54).
Model building
An apo-TR1 LBD model was built using both ER LBD
structure complexedwith antagonist 4-hydroxytamoxifen (PDB
ID 3ERT) (38) and the TR1 LBD structure (PDB ID 3GWS)
(10) as templates. The sequences were aligned using ClustalW
software (55). For the alignment, we used the entire sequence of
TR1 LBD, part of TR1 structure, from helix 0 to helix 11
(PDB ID 3GWS), and the ER structure in inactive conforma-
tion (PDB ID 3ERT) to modify the conformation of helix 12.
The model was constructed using MODELLER 9v4 software
(56). For a given alignment, 10 model structures were built and
evaluated with the PROCHECK software suite (57). All models
were similar, and only the best-evaluated model was retained
after the analysis.
Mutations and transactivation analyses
The plasmids pCMV-TR1, pCMV-TR1 mutants, and
TRE-F2-2x1 luciferase reporter for mammals transcription as-
says were described previously (58, 59). New TR mutants re-
ported in the present study (pCMX vectors) were created from
existing vectors using QuikChange site-directed mutagenesis
kits (Stratagene, La Jolla, CA). The mutations were verified by
DNA sequencing.
For transactivation assays, HeLa cells were seeded into 24-
well plates at a density of 1105 cells per well and grown in
10% FBS-DMEM under 95% air and 5% CO2 at 37 C over-
nightwith 2mMglutamine and 50g/ml streptomycin. The cells
were then cotransfected with 10 ng of pCMV-TR1 and with
100 nM TRE (F2) linked with luciferase reporter. The plasmid
pRL containing the Renilla luciferase gene was transfected si-
multaneously and used as a control. TransFectin lipid reagent
(Bio-Rad, Hercules, CA) was mixed with plasmids in DMEM
and incubated at room temperature for 20 min before adding to
the culture medium. The ratio of DNA (micrograms) to Trans-
Fectin (microliters) was 1:3 (wt/vol). T3was subsequently added
to the culture medium 4 h later and was incubated with the cells
overnight. For activation assays, the ligand concentration in the
cultures was kept at 107 M.
For luciferase assays, the cell monolayer was washed with
PBS and harvested with lysis buffer (dual-luciferase reporter
assay system; Promega,Madison,WI) andmeasured in a Safire2
luminescent counter (Tecan, Durham, NC). Renilla luciferase
activity was measured in the same lysate to adjust variation
caused by transfection efficiencies. Luciferase assays were per-
formed as previously described (58, 59).
MD simulations
The complete simulated systems were built with Packmol
(60, 61), containing the LBD of TR, water, and one counterion
for each charged residue for electroneutrality. We used a cubic
box with 16,600 water molecules with side dimensions of 81 Å.
The average thickness of the LBD hydration layer is approxi-
mately 25 Å. The initial protein structure was the T3-TR LBD
complex in the holo conformation (PDB ID 3GWS) (10), from
which the ligand was deleted.
All simulations were performed with NAMD (62), apply-
ing periodic boundary conditions, a time step of 2.0 fsec, and
CHARMM parameters (63). The TIP3P model was used for
water (64). All hydrogen-to-heavy-atom bonds were kept rigid.
A 14-Å cutoff with smooth switching function starting at 12 Å
was used for the van der Waals interactions, whereas electro-
static forces were treated via the particle mesh Ewald method
(65). Energy minimization was performed as follows. The en-
ergy of the system was minimized by 700 conjugate gradient
(CG) steps keeping all protein atoms fixed, except the modeled
28 Figueira et al. Agonist and Antagonist Conformation of TR1 Mol Endocrinol, January 2011, 25(1):15–31
regions, whichwere always allowed tomove. Fixing only the C
atoms, another 500 CG steps were performed. Finally, 300 CG
steps were carried out without any restrictions.
After this procedure, 22-nsec MD simulations were per-
formed under constant number of particles, temperature, and
pressure conditions (NpT ensemble) at 298 K and 1 bar, with
velocity rescaling every 2 psec and Langevin barostat with
damping coefficient of 5 psec1. The first 2 nsec were discarded
for equilibration of the system. We carried out three indepen-
dent simulations with this protocol. To capture events of signif-
icant conformational changes during the course of the simulated
protein motions, we performed a set of three additional simu-
lations of the same system at the canonical ensemble with con-
stant temperature of 498 K and 1 g/cm3 density (see for instance
Ref. 47). The initial configurations for these runs, taken from
the last step of 298 K simulations, were thermalized at 498 K
by rescaling atomic velocities every 0.1 psec with a Berendsen
thermostat during 500 psec before starting the set of 20-nsec
production runs.
We characterized the helix H12 conformation with the
RMSD computed by aligning each frame to two different refer-
ences (the holo-TR LBD and the proposed ER-TR hybrid
model) with the algorithm described by Kearsley (66). The in-
dependent structures with lowest RMSD relative to the hybrid
model were used as starting configurations for 298 K anneal-
ing simulations. These runs lasted for about 20 nsec each. The
average apo structures shown in Fig. 7, C and D, and Sup-
plemental Fig. 2 were obtained from the last 5-nsec portion of
these trajectories.
Acknowledgments
We thank J. R. C.Muniz for helping uswith TexShade software.
Address all correspondence and requests for reprints to: Igor
Polikarpov, Universidade de Sa˜o Paulo, Departamento Física e
Informa´tica, Instituto de Física, Avenida Trabalhador Sa˜ocarlense,
400, Sa˜o Carlos, SP, Brazil 13560-970. E-mail: ipolikarpov@
ifsc.usp.br.
This work was supported by the Conselho Nacional de Des-
envolvimento Científico e Tecnolo´gico (CNPq) IP (300220/96-
0), by Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo
(FAPESP) Grants 03/09462-5, 06/00182-8, and 08/00078-1
and National Institutes of Health Grants DK41482 and 51281
to J.D.B.
Disclosure Summary: The authors have nothing to disclose.
References
1. Laudet V, Gronemeyer H 1995 The nuclear receptors facts book.
London: Academic Press; 1–109
2. Glass CK, Rosenfeld MG 2000 The corregulator exchange in tran-
scriptional functions of nuclear receptors. Genes Dev 14:121–141
3. Lazar MA, Chin WW 1990 Nuclear thyroid receptor. J Clin Invest
86:1777–1782
4. Ribeiro RC, Apriletti JW, Wagner RL, West BL, Feng W, Huber R,
Kushner PJ, Nilsson S, Scanlan T, Fletterick RJ, Schaufele F, Baxter
JD 1998 Mechanisms of thyroid hormone action: insights from
x-ray crystallographic and functional studies. Recent Prog Horm
Res 53:351–394
5. Swanson EA, Gloss B, Belke DD, Kaneshige M, Cheng SY,
Dillmann WH 2003 Cardiac expression and function of thyroid
hormone receptor and its mutant. Endocrinology 144:4820–4825
6. Baxter JD, DillmannWH,West BL, Huber R, Furlow JD, Fletterick
RJ, Webb P, Apriletti JW, Scanlan TS 2001 Selective modulation of
thyroid hormone receptor action. J Steroid Biochem Mol Biol 76:
31–42
7. Nagy L, Schwabe JWR 2004 Mechanism of the nuclear receptor
molecular switch. Trends Biochem Sci 29:317–324
8. Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST,
Scanlan TS, Apriletti JW, Baxter JD, West BL, Fletterick RJ 2001
Hormone selectivity in thyroid hormone receptors. Mol Endocrinol
15:398–410
9. Darimont BD, Wagner RL, Apriletti JW, StallcupMR, Kushner PJ,
Baxter JD, Fletterick RJ, Yamamoto KR 1998 Structure and spec-
ificity of nuclear receptor-coactivator. Genes Dev 12:3343–3356
10. Nascimento AS, Dias SM, Nunes FM, Aparício R, Ambrosio AL,
Bleicher L, Figueira AC, SantosMA, deOliveiraNetoM, FischerH,
TogashiM, Craievich AF, Garratt RC, Baxter JD,Webb P, Polikar-
pov I 2006 Structural rearrangements in the thyroid hormone re-
ceptor hinge domain and their putative role in the receptor function.
J Mol Biol 360:586–598
11. Togashi M, Borngraeber S, Sandler B, Fletterick RJ, Webb P,
Baxter JD 2005 Conformational adaptation of nuclear receptor
ligand binding domains to agonists: potential for novel approaches
to ligand design. J Steroid Biochem Mol Biol 93:127–137
12. Ribeiro RC, Feng W, Wagner RL, Costa CH, Pereira AC, Apriletti
JW, Fletterick RJ, Baxter JD 2001 Definition of the surface in the
thyroid hormone receptor ligand binding domain for association as
homodimers and heterodimers with retinoid X receptor. J Biol
Chem 276:14987–14995
13. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH,
Williams SP, Willson TM, Kliewer SA, Redinbo MR 2001 The
human nuclear xenobiotic receptor PXR: structural determinants
of directed promiscuity. Science 292:2329–2333
14. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG,
Engstro¨m O, Ljunggren J, Gustafsson JA, Carlquist M 1999 Struc-
ture of the ligand-binding domain of oestrogen receptor  in the
presence of a partial agonist and a full antagonist. EMBO J 18:
4608–4618
15. Wurtz JM, BourguetW,Renaud JP, Vivat V, Chambon P,MorasD,
Gronemeyer H 1996 A canonical structure for the ligand binding
domain of nuclear receptors. Nat Struct Biol 3:87–94
16. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995
Crystal structure of the ligand-binding domain of the human nu-
clear receptor RXR-R. Nature 375:377–382
17. Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson JA,
Pike AC 2007 Structural insights into corepressor recognition by
antagonist-bound estrogen receptors. J Biol Chem 282:10449–10455
18. Webb P, Nguyen NH, Chiellini G, Yoshihara HA, Cunha Lima ST,
Apriletti JW, Ribeiro RC, Marimuthu A, West BL, Goede P,
Mellstrom K, Nilsson S, Kushner PJ, Fletterick RJ, Scanlan TS,
Baxter JD 2002 Design of thyroid receptor antagonists from first
principles. J Steroid Biochem Mol Biol 83:59–73
19. Kosztin D, Izrailev S, Schulten K 1999 Unbinding of retinoic acid
from its receptor studied by steered molecular dynamics. Biophys J
76:188–197
20. JohnsonBA,Wilson EM, Li Y,Moller DE, SmithRG,ZhouG 2000
Ligand-induced stabilization of PPAR monitored by NMR spec-
troscopy: implications for nuclear receptor activation. J Mol Biol
298:187–194
21. Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern
MR, Griffin PR 2006 Hydrogen/deuterium exchange (H/D-Ex) of
PPAR LBD in the presence of various modulators. Protein Sci
15:1883–1892
22. Frego L, Davidson W 2006 Conformational changes of the glu-
cocorticoid receptor ligand binding domain induced by ligand and
cofactor binding, and the location of cofactor binding sites deter-
Mol Endocrinol, January 2011, 25(1):15–31 mend.endojournals.org 29
mined by hydrogen/deuterium exchange mass spectrometry. Pro-
tein Sci 15:722–730
23. Yan X, Broderick D, Leid ME, Schimerlik MI, Deinzer ML 2003
Dynamics and ligand-induced solvent accessibility changes in hu-
man retinoid X receptor homodimer determined by hydrogen deu-
terium exchange andmass spectrometry. Biochemistry 43:909–917
24. Pissios P, Tzameli I, Kushner P, Moore DD 2000 Dynamic stabili-
zation of nuclear receptor ligand binding domains by hormone or
corepressor binding. Mol Cell 6:245–253
25. Huber BR, Sandler B, West BL, Cunha Lima ST, Nguyen HT,
Apriletti JW, Baxter JD, Fletterick RJ 2003 Two resistance to thy-
roid hormone mutants with impaired hormone binding. Mol En-
docrinol 17:643–652
26. Huber BR, Desclozeaux M, West BL, Cunha-Lima ST, Nguyen
HT, Baxter JD, Ingraham HA, Fletterick RJ 2003 Thyroid hor-
mone receptor- mutations conferring hormone resistance and re-
duced corepressor release exhibit decreased stability in the N-ter-
minal ligand-binding domain. Mol Endocrinol 17:107–116
27. Shah V, Nguyen P, Nguyen NH, Togashi M, Scanlan TS, Baxter
JD, Webb P 2008 Complex actions of thyroid hormone receptor
antagonist NH3 on gene promoters in different cell lines. Mol Cell
Endocrinol 296:69–77
28. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T,
Engstro¨m O, Ohman L, Greene GL, Gustafsson JA, Carlquist M
1997 Molecular basis of agonism and antagonism in the estrogen
receptor. Nature 389:753–758
29. Engen JR, Gmeiner WH, Smithgall TE, Smith DL 1999 Hydrogen
exchange shows peptide binding stabilizes motions in Hck SH2.
Biochemistry 38:8926–8935
30. Chalmers MJ, Busby SA, Pascal BD, He Y, Hendrickson CL,
Marshall AG, Griffin PR 2006 Probing protein ligand interactions
by automated hydrogen/deuterium exchange mass spectrometry.
Anal Chem 78:1005–1014
31. Englander JJ., DelMar C, LiW, Englander SW, Kim JS, Stranz DD,
Hamuro Y, Woods Jr VL 2003 Protein structure change studied by
hydrogen-deuterium exchange, functional labeling, and mass spec-
trometry. Proc Natl Acad Sci USA 100:7057–7062
32. Dai SY, Burris TP, Dodge JA, Montrose-Rafizadeh C, Wang Y,
Pascal BD, Chalmers MJ, Griffin PR 2009 Unique ligand binding
patterns between estrogen receptor  and  revealed by hydrogen-
deuterium exchange. Biochemistry 48:9668–9676
33. Yan X, Pe´rez E, Leid M, Schimerlik MI, de Lera AR, Deinzer ML
2007 Deuterium exchange and mass spectrometry reveal the inter-
action differences of two synthetic modulators of RXR LBD. Pro-
tein Sci 16:2491–2501
34. Chandra V, Huang P, Hamuro Y, Raghuram S,Wang Y, Burris TP,
Rastinejad F 2008 Structure of the intact PPAR--RXR- nuclear
receptor complex on DNA. Nature 456:350–356
35. Elhaji YA, Stoica I, Dennis S, Purisima EO, Lumbroso R, Beitel LK,
Trifiro MA 2006 Impaired helix 12 dynamics due to proline 892
substitutions in the androgen receptor are associated with complete
androgen insensitivity. Hum Mol Genet 15:921–931
36. McGee TD, Edwards J, Roitberg AE 2008 Preliminary molecular
dynamic simulations of estrogen receptor  ligand binding domain
from antagonist to apo. Int J Environ Res Public Health 5:111–114
37. Celik L, Lund JD, Schiøtt B 2007 Conformational dynamics of the
estrogen receptor : molecular dynamics simulations of the influ-
ence of binding site structure on protein dynamics. Biochemistry
46:1743–1758
38. Sonoda MT, Martínez L, Webb P, Skaf MS, Polikarpov I 2008
Ligand dissociation from estrogen receptor is mediated by receptor
dimerization: evidence from molecular dynamics simulations. Mol
Endocrinol 22:1565–1578
39. Martínez L, Webb P, Polikarpov I, Skaf MS 2006 Molecular Dy-
namics simulations of ligand dissociation from thyroid hormone
receptors: evidence of the likeliest escape pathway and its implica-
tions for the design of novel ligands. J Med Chem 49:23–26
40. Martínez L, Sonoda MT, Webb P, Baxter JD, Skaf MS, Polikarpov
I 2005 Molecular dynamics simulations reveal multiple pathways
of ligand dissociation from thyroid hormone receptors. Biophys J
89:2011–2023
41. Martínez L, Nascimento AS, Nunes FM, Phillips K, Aparicio R,
Dias SM, Figueira ACM, Lin JH,Nguyen P, Apriletti JW,Neves FA,
Baxter JD, Webb P, Skaf MS, Polikarpov I 2009 Gaining ligand
selectivity in thyroid hormone receptors via entropy. Proc Natl
Acad Sci USA 106:20717–20722
42. Figueira AC, Neto Mde O, Bernardes A, Dias SM, Craievich AF,
Baxter JD,Webb P, Polikarpov I 2007 Low-resolution structures of
thyroid hormone receptor dimers and tetramers in solution. Bio-
chemistry 46:1273–1283
43. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA,
Greene GL 1998 The structural basis of estrogen receptor/coacti-
vator recognition and the antagonism of this interaction by tamox-
ifen. Cell 95:927–937
44. Zhang J, HuX, LazarMA 1999A novel role for helix 12 of retinoid
X receptor in regulating repression. Mol Cell Biol 19:6448–6457
45. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Flett-
erick RJ, Baxter JD, West BL 2002 TR surfaces and conformations
required to bind nuclear receptor corepressor. Mol Endocrinol 16:
271–286
46. Togashi M, Nguyen P, Fletterick R, Baxter JD, Webb P 2005 Re-
arrangements in thyroid hormone receptor charge clusters that sta-
bilize bound 3,5,5-triiodo-L-thyronine and inhibit homodimer for-
mation. J Biol Chem 280:25665–25673
47. Martínez L, Souza PC, Garcia W, Batista FA, Portugal RV,
Nascimento AS, Nakahira M, Lima LM, Polikarpov I, Skaf MS
2010 On the denaturation mechanisms of the ligand binding do-
main of thyroid hormone receptors. J Phys ChemB114:1529–1540
48. Este´banez-Perpin˜a´ E, Arnold LA, Arnold AA, Nguyen P, Rodrigues
ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK,
Webb P, Fletterick RJ 2007 A surface on the androgen receptor that
allosterically regulates coactivator binding. ProcNatl Acad Sci USA
104:16074–16079
49. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD,
Fletterick RJ 1995 A structural role for hormone in the thyroid
hormone receptor. Nature 378:690–697
50. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD,
Scanlan TS 2002 Rational design and synthesis of a novel thyroid
hormone antagonist that blocks coactivator recruitment. J Med
Chem 45:3310–3320
51. Figueira AC, Dias SM, Santos MA, Apriletti JW, Baxter JD, Webb
P, Neves FA, Simeoni LA, Ribeiro RC, Polikarpov I 2006 Human
thyroid receptor forms tetramers in solution, which dissociate into
dimers upon ligand binding. Cell Biochem Biophys 44:453–462
52. Clauser KM, Baker P, Burlingame AL 1999 Role of accurate mass
measurement (/ 10 ppm) in protein identification strategies em-
ploying MS or MS/MS and database searching. Anal Chem 71:
2871–2882
53. Kabsch W, Sander C 1983 Dictionary of protein secondary struc-
ture: pattern recognition of hydrogen-bonded and geometrical fea-
tures. Biopolymers 22:2577–2637
54. Beitz E 2000 TeXshade: shading and labeling of multiple sequence
alignments using LaTeX2e. Bioinformatics 16:135–139
55. Thompson JD, Higgins DG, Gibson TJ 1994 CLUSTAL W: im-
proving the sensitivity of progressive multiple sequence alignment
through sequence weighting, position-specific gap penalties and
weight matrix choice. Nucleic Acids Res 22:4673–4680
56. Sali A, Blundell TL 1993 Comparative protein modeling by satis-
faction of spatial restraints. J Mol Biol 234:779–815
57. Laskowski RA, MacArthur MW, Moss DS, Thornton JM 1993
PROCHECK: a program to check the stereochemical quality of
protein structures. J Appl Crystallogr 26:283–291
58. Feng W, Ribeiro RCJ, Wagner RL, Nguyen H, Apriletti JW,
Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-
dependent coactivator binding to a hydrophobic cleft on nuclear
receptors. Science 5370:1747–1749
30 Figueira et al. Agonist and Antagonist Conformation of TR1 Mol Endocrinol, January 2011, 25(1):15–31
59. Velasco LF, Togashi M, Walfish PG, Pessanha RP, Moura FN,
Barra GB, Nguyen P, Rebong R, Yuan C, Simeoni LA, Ribeiro RC,
Baxter JD, Webb P, Neves FA 2007 Thyroid hormone response
element organization dictates the composition of active receptor.
J Biol Chem 282:12458–12466
60. Martínez JM, Martínez L 2003 Packing optimization for auto-
mated generation of complex system’s initial configurations for
molecular dynamics and docking. J Comput Chem 24:819–825
61. Martínez L, Andrade R, Birgin EG, Martínez JM 2009 A package
for building initial configurations for molecular dynamics simula-
tions. J Comput Chem 30:2157–2164
62. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E,
Chipot C, Skeel RD, Kale´ L, Schulten K 2005 Scalable molecular
dynamics with NAMD. J Comput Chem 26:1781–1802
63. MacKerell AD, BashfordD, BellottM,DunbrackRL, Evanseck JD,
Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D,
Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T,
Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M,
Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J,
Yin D, Karplus M 1998 All-atom empirical potential for molecular
modeling and dynamics studies of proteins. J Phys Chem B 102:
3586–3616
64. JorgensenWL,Chandrasekhar J,Madura JD, ImpeyRW,KleinML
1983 Comparison of simple potential functions for simulating liq-
uid water. J Chem Phys 79:926–935
65. Darden T, York D, Pedersen L 1993 Particle mesh Ewald: an
Nlog(N) method for Ewald sums in large systems. J Chem Phys
98:10089–10092
66. Kearsley SK 1989On the orthogonal transformation used for struc-
tural comparisons. Acta Cryst A 45:208–210
Go to the Translational Research in 
Endocrinology & Metabolism site for a collection 
of articles from The Endocrine Society journals 
www.endojournals.org/trem
Mol Endocrinol, January 2011, 25(1):15–31 mend.endojournals.org 31
